SAFE HANDLING RESOURCES: FAQs
Each year millions of healthcare workers are exposed to chemotherapy and other hazardous drugs while they are preparing and administering drug therapies to patients. These instances of exposure have been known to cause severe health effects, including: the development of new cancers, infertility, birth defects, liver/kidney failures, and many other serious adverse medical conditions. Studies show that nurses, pharmacists, other caregivers and even patients and their visitors in chemotherapy units are routinely exposed to carcinogenic or otherwise toxic agents. Healthcare providers are increasingly committed to finding safer technologies and procedures for preparing and delivering hazardous pharmaceuticals.
Several government and industry-sponsored associations have corroborated the prevalence of worker exposure and workplace contamination and studies have confirmed the severity of the resulting health risks. In fact in April 2011, OSHA, NIOSH and the Joint Commission released a public statement acknowledging that “every day in healthcare settings across America, workers are exposed to hundreds of powerful drugs used for cancer chemotherapy, antiviral treatments, hormone regimens and other therapies…Some of these drugs have been known to cause cancer, reproductive and developmental problems, allergic reactions, and other adverse effects that can be irreversible even after low-level exposures.” To read the full statement click here.
A CSTD is defined as a device that “mechanically prohibits the transfer of contaminants into the system and the escape of vapors out of the system.” This new industry standard definition is supported by several industry focused groups, including: Occupational Safety & Health Administration (OSHA), National Institute of Occupational Safety & Health (NIOSH), United States Pharmacopeia (USP), American Society of Health-Systems Pharmacists (ASHP), Oncology Nursing Society (ONS), and the International Society of Oncology-Pharmacy Practitioners (ISOPP).
Unfortunately, yes. While Personal Protective Equipment provides a base layer of protection, studies have shown that despite having PPE in place there is still a risk of exposure as result of medication error or more frequently mishandling. Healthcare workers and patients can fall victim to exposure from liquid spills and vapor leakage.
USP 800 is the new standard of protective protocols for the safe handling of hazardous drugs from the United States Pharmacopia. It will exert more stringent safe handling recommendations for the industry, including the use of Closed System Transfer Devices. The revised General Chapter will be published on February 1, 2016 in the First Supplement to USP 39–NF 34. Additionally, the Expert Committee approved a delayed official implementation date of July 1, 2018 to allow entities more than two years to implement the chapter. See more here.
Borne from a passion to make cancer care safer for healthcare providers and patients, Corvida Medical® co-founders Jared Garfield and John Slump have dedicated years to innovating intelligent technologies that represent smarter solutions for the safe handling of hazardous drugs. The entrepreneurs discovered that each year, millions of healthcare workers are routinely exposed to the hazardous drugs used to treat patients, significantly increasing their risk for cancers, infertility, miscarriages, birth defects, genetic mutations, and more. The end result of their inquisitive passion and dedication to finding a solution is Corvida Medical®, a leading edge medical device firm that addresses the problems inherent in current methods to develop smarter, simpler solutions that improve safety, productivity and quality for providers and patients. The industry-experienced team that they have assembled is committed to developing novel technologies that enable healthcare providers to safely deliver the highest quality of care to their patients.